AGM
ATNM icon

Alpine Global Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Alpine Global Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-566
Closed -$45K – 146
2015
Q2 		$45K Buy
+566
New +$48.3K 0.01% 799

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Alpine Global Management's ATNM Position: Q3 2015 in Review

Alpine Global Management sold out of Actinium Pharmaceuticals (ATNM) in Q3 2015, closing a stake of 566 shares — an estimated $45K sold.

Alpine Global Management first reported a position in ATNM in Q2 2015 and held it in 1 quarter. The position peaked at $45K in Q2 2015. 27 funds tracked by Wall St. Rank hold ATNM as of Q3 2015.

  • Alpine Global Management reported no remaining Actinium Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Alpine Global Management sold 566 Actinium Pharmaceuticals shares in Q3 2015, an estimated $45K.
  • Alpine Global Management first reported a position in Actinium Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Alpine Global Management's Actinium Pharmaceuticals position peaked at $45K in Q2 2015.
  • 27 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2015.

Based on Alpine Global Management's 13F filing for Q3 2015, filed 10 Nov 2015.